Author response: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
Year: 2016
Type: peer-review
Abstract: GDC-0810 is a novel, orally bioavailable SERD that exhibits robust pre-clinical activity in models of ER+ breast cancer, including models of tamoxifen resistance, and those that express the ERα mutations, ER.Y537S and ER.D538G.
Authors: James D Joseph, Beatrice Darimont, Wei Zhou, Alfonso Arrazate, Amy Young, Ellen Ingalla, Kimberly Walter, Robert A Blake, Jim Nonomiya, Zhengyu Guan, Lorna Kategaya, Steven P Govek, Andiliy G Lai, Mehmet Kahraman, Dan Brigham, John Sensintaffar, Nhin Lu, Gang Shao, Jing Qian, Kate Grillot, Michael Moon, Rene Prudente, Eric Bischoff, Kyoung-Jin Lee, Celine Bonnefous, Karensa L Douglas, Jackaline D Julien, Johnny Y Nagasawa, Anna Aparicio, Josh Kaufman, Benjamin Haley, Jennifer M Giltnane, Ingrid E Wertz, Mark R Lackner, Michelle A Nannini, Deepak Sampath, Luis Schwarz, Henry Charles Manning, Mohammed Noor Tantawy, Carlos L Arteaga, Richard A Heyman, Peter J Rix, Lori Friedman, Nicholas D Smith, Ciara Metcalfe, Jeffrey H Hager
Institutions: Genentech, Vanderbilt University, Vanderbilt-Ingram Cancer Center
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4232882208